Bristol-Myers to present immuno-oncology therapy data at AACR 2017
Bristol-Myers Squibb announced that new clinical data will be presented at the American Association for Cancer Research Annual Meeting 2017 in Washington, D.C., from April 1-5. Research to be presented represents the company's ongoing commitment to investigating long-term survival and safety data in advanced cancers, and to exploring the interaction between biomarkers and Immuno-Oncology therapy across multiple tumor types. Results will be disclosed for Opdivo, as a single-agent and in combination with Yervoy, as well as an investigational, optimized, once-daily IDO1 inhibitor alone or in combination with Opdivo. IDO is part of Bristol-Myers Squibb's robust early clinical development pipeline and one of 21 oncology compounds in clinical study. Bristol-Myers Squibb will also share data generated as part of the International Immuno-Oncology Network, a global peer-to-peer collaboration with academia established in 2012 and focused on advancing the science of I-O through a series of preclinical, translational and biology-focused research objectives. "At Bristol-Myers Squibb, we are committed to translational research as we advance the development of next-generation Immuno-Oncology therapies and conduct biomarker research that will help us determine which patients are most likely to benefit from our treatments," said Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb. "In all of our research efforts, we are driven by our overarching goal of changing the way patients live with cancer."